

Curriculum Vitae

Personal information **Joep Bergers**

Work experience

1. Employer: Medicines Evaluation Board (MEB)
 - Start date: 2011
 - End date:
 - Position: Assessor quality biological medicinal products
 - Activities: Assessment of the chemical_pharmaceutical_biological sections of licensing applications of biological product; Scientific advices
 - Country: Netherlands
2. Employer: National Institute for Public Health and the Environment
 - Start date: 1994
 - End date: 2011
 - Position: (senior) Scientist
 - Activities: Project leader Official Control Authority Batch Release (OCABR) of vaccines and blood products; responsible for laboratory testing and OCABR of vaccines and blood products; Assessment of the chemical_pharmaceutical_biological section of licensing applications of biological product
 - Country: Netherlands
3. Employer: Erasmus University Rotterdam
 - Start date: 1992
 - End date: 1994
 - Position: Postdoc Microbiology
 - Activities: Research
 - Country: Netherlands

Education and training

1. Subject: Utrecht University
 - Start date: 1988
 - End date: 1992
 - Qualification: Ph.D. in Science
 - Organisation: Research and training in drug delivery. Thesis: Liposomes as vehicles for proteins. Mode of protein association & application in tumour immunology.
 - Country: Netherlands
2. Subject: Utrecht University
 - Start date: 1986
 - End date: 1987
 - Qualification: Pharmacist
 - Organisation: Qualification as a pharmacist
 - Country: Netherlands
3. Subject: Utrecht University
 - Start date: 1979
 - End date: 1986
 - Qualification: M. Sc. Pharmacy
 - Organisation:
 - Country: Netherlands

Additional information

Publications

- Bergers, J., Wassenaar C., and Bos, R. (2007) RIVM/BMT –Rijkscontrolelaboratorium voor Biologische Geneesmiddelen: Elke partij vaccins wordt dubbel en onafhankelijk gecontroleerd. Infectieziekten Bulletin 18, 167 – 170.
- Van Slooten, M.L., Koppenhagen, F.J., Bergers, J.J., Kircheis, R., Crommelin, D.J.A., Wagner, E. and Storm, G. (1998) Liposomal delivery of cytokines for anticancer vaccination. In: Diederichs, J.E. and Müller, R.H. (Eds.), Future Strategies for Drug Delivery with Particulate Systems, Medpharm Scientific Publishers, Stuttgart, DE, pp.184-188.
- Bergers, J.J., Hengge, U.R., Snijders, S.V. and Bakker_Woudenberg, I.A.J.M. (1997) Inhibition of cytomegalovirus late_antigen expression and cytomegalovirus replication in human fibroblasts and differentiated monocytic cells by liposome-encapsulated foscarnet. J. Contr. Rel. 47, 163-171.
- Bergers, J.J., Den Otter, W. and Crommelin, D.J.A. (1996) Liposome-based cancer vaccines. J. Liposome Res. 6, 339_355.
- Bergers, J.J., Van Bloois, L., Barenholz, Y. and Crommelin, D.J.A. (1995) Conformational changes of myoglobin upon interaction with negatively-charged phospholipid vesicles. J. Liposome Res. 5, 311-326.
- Bergers, J.J., Ten Hagen, T.L.M., Van Etten, E.W.M. and Bakker_Woudenberg, I.A.J.M. (1995) Liposomes as delivery systems in the prevention and treatment of infectious diseases. Pharmacy World Science 17, 1-11.
- Bergers, J.J., Den Otter, W. and Crommelin, D.J.A. (1994) Vesicles for tumour-associated antigen presentation to induce protective immunity: preparation, characterization and enhancement of the immune response by immunomodulators. J. Contr. Rel. 29, 317-327.

Bergers, J.J., Den Otter, W., Dullens, H.F.J., De Groot, J.W., Steerenberg, P.A., Filius, P.M.G. and Crommelin, D.J.A. (1994) Effect of immunomodulators on specific tumor immunity induced by liposome encapsulated tumor-associated antigens. *Int. J. Cancer* 56, 721-726.

Bergers, J.J., Den Otter, W., Dullens, H.F.J., Kerkvliet, C.T.M. and Crommelin, D.J.A. (1993) Interleukin-2-containing liposomes: Interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines. *Pharm. Res.* 10, 1715-1721.

Bergers, J.J., Den Otter, W., Dullens, H.F.J., De Groot, J.W., Steerenberg, P.A., Mimpfen, M.W.H. and Crommelin, D.J.A. (1993) Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice. *Cancer Immunol. Immunother.* 37, 271-279.

Bergers, J.J., Vingerhoeds, M.H., Van Bloois, L., Herron, J.N., Janssen, L.H.M., Fischer, M.J.E. and Crommelin, D.J.A. (1993) The role of protein charge in protein-lipid interactions. pH-dependent changes of the electrophoretic mobility of liposomes through adsorption of water-soluble, globular proteins. *Biochemistry (USA)* 32, 4641-4649

Bergers, J.J., Storm, G. and Den Otter, W. (1993) Liposomes as vehicles for the presentation of tumor-associated antigens to the immune system. In: Gregoriadis, G. (Ed.), *Liposome Technology, Volume II*, 2nd Edition, CRC Press, Boca Raton, FL, pp. 141-166.

Crommelin, D.J.A., Bergers, J.J. and Zuidema, J. (1992) Antibody-based drug targeting approaches: perspectives and challenges. In: Wermuth, C.G. (Ed.), *Medical Chemistry for the 21st Century*, Blackwell Scientific Publications, Oxford, UK, pp. 351-365.

Vendrik, C.P.J., Bergers, J.J., De Jong, W.H. and Steerenberg, P.A. (1992) Resistance to cytostatic drugs at the cellular level. *Cancer Chemother. Pharmacol.* 29, 413-429.

Bergers, J.J., Den Otter, W., De Groot, J.W., De Blois, A.W., Dullens, H.F.J., Steerenberg, P.A. and Crommelin, D.J.A. (1992) Reconstituted membranes of tumour cells (proteoliposomes) induce specific protection to murine lymphoma cells. *Cancer Immunol. Immunother.* 34, 233-240.

Steerenberg, P.A., Storm, G., De Groot, G., Claessen, A., Bergers, J.J., Franken, M.A.M., Van Hoesel, Q.G.C.M., Wubs, K.L. and De Jong, W.H. (1988) Liposomes as drug carrier system for cis_diamminedichloroplatinum (II) II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution. *Cancer Chemother. Pharmacol.* 21, 299-307.

Steerenberg, P.A., Storm, G., De Groot, G., Bergers, J.J., Claessen, A. and De Jong, W.H. (1987) Liposomes as drug carrier system for cis_diamminedichloroplatinum (II) I. Binding capacity, stability and tumor cell growth inhibition in vitro. *Int. J. Pharm.* 41, 51-62.

Projects

Memberships

1997 - present: European Pharmacopoeia, member of Group 15 (Human Vaccines and Sera)

2000 - 2011: member of the OCABR drafting group for vaccines for human use (EDQM, Strasbourg).

Other Relevant Information